pathological responce rate
Showing 1 - 25 of >10,000
Simple Blood Test to Reduce Unnecessary Adverse Effects From
Not yet recruiting
- Pathological Response Rate, Circulating Tumour DNA
- MeD-seq
- (no location specified)
Sep 6, 2023
Gastric Cancer Trial in Mykolaiv (Docetaxel, Oxaliplatin, Leucovorin)
Active, not recruiting
- Gastric Cancer
- Docetaxel
- +4 more
-
Mykolaiv, UkraineUkrainian Society of Clinical Oncology
Apr 11, 2022
High-risk Locally Advanced Colorectal Cancer, Neoadjuvant Chemo, FOLFOXIRI Regimen Trial in Chengdu (Oxaliplatin, Irinotecan,
Recruiting
- High-risk Locally Advanced Colorectal Cancer
- +2 more
- Oxaliplatin
- +4 more
-
Chengdu, Sichuan, ChinaSichuan University West China Hospital
Aug 18, 2021
Fasting Mimicking Diet, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer Trial in Netherlands (Fasting
Not yet recruiting
- Fasting Mimicking Diet
- +5 more
- Fasting Mimicking diet program
-
Alkmaar, Netherlands
- +14 more
Aug 15, 2022
Adenocarcinoma of Esophagogastric Junction Trial in Beijing (neoadjuvant Radiation plus SOX and PD-1 antibody)
Not yet recruiting
- Adenocarcinoma of Esophagogastric Junction
- neoadjuvant Radiation plus SOX and PD-1 antibody
-
Beijing, Beijing, ChinaPeking University People's Hospital
Aug 15, 2022
Prostate Cancer Trial in Canada (Abiraterone acetate with prednisone, Leuprolide, Cabazitaxel with peg-filgrastim)
Completed
- Prostate Cancer
- Abiraterone acetate with prednisone
- +2 more
-
Vancouver, British Columbia, Canada
- +4 more
Apr 13, 2022
Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)
Not yet recruiting
- Hepatocellular Carcinoma
- +5 more
- TACE
- Tislelizumab, Lenvatinib
-
Hangzhou, Zhejiang, China1# Banshan East Rd. Zhejiang cancer hospital
Jun 17, 2023
Bone Metastases, Pathological Fracture, Pathological Fracture, Left Femur Trial (Internal fixation with short intramedullary
Not yet recruiting
- Bone Metastases
- +4 more
- Internal fixation with short intramedullary nails
- Internal fixation with long intramedullary nails
- (no location specified)
Jul 23, 2023
NSCLC Trial in Nanchang, Shanghai (KN046 plus Axitinib)
Recruiting
- NSCLC
- KN046 plus Axitinib
-
Nanchang, Jiangxi, China
- +1 more
Aug 27, 2023
Intraoperative Frozen Section Pathology to Guide Surgical
Recruiting
- Lung Adenocarcinoma
- +2 more
- Surgical resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Mar 20, 2023
Immune Suppression, Gastric Cancer Trial in Hangzhou (nivolumab combined with SOX)
Recruiting
- Immune Suppression
- Gastric Cancer
- nivolumab combined with SOX
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Feb 11, 2023
Esophageal Squamous Cell Carcinoma Trial in Chongqing (Tislelizumab)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
-
Chongqing, Chongqing, ChinaArmy Medical Center of the People's Liberation Army
May 26, 2023
Endometrial Tumors, Endometrial Cancer Trial in Seoul (Nivolumab)
Not yet recruiting
- Endometrial Neoplasms
- Endometrial Cancer
-
Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
Mar 21, 2023
Colonic Tumors Trial in Moscow (Japanese pathological investigation, European pathological investigation)
Not yet recruiting
- Colonic Neoplasms
- Japanese pathological investigation
- European pathological investigation
-
Moscow, Russian FederationClinic of coloproctology and minimally invasive surgery
Nov 1, 2023
Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma
Recruiting
- Esophageal Squamous Cell Carcinoma
-
Shijiazhuang, Hebei, ChinaDepartment of Thoracic Surgery, Fourth Hospital of Hebei Medical
Oct 25, 2023
Triple Negative Breast Tumors Trial (Xiaopi granules, Xiaopi decoction, Placebo)
Not yet recruiting
- Triple Negative Breast Neoplasms
- Xiaopi granules
- +2 more
- (no location specified)
Nov 22, 2023
Soft Tissue Sarcoma Trial in Zhengzhou (Piamprimab (AK105))
Not yet recruiting
- Soft Tissue Sarcoma
- Piamprimab (AK105)
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital
Jan 30, 2023
Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course
Recruiting
- Locally Advanced Rectal Cancer
- Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
- Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Apr 25, 2023
Brain Tumor, Brain Cancer Trial in Taipei (mesoscale nonlinear optical microscope)
Recruiting
- Brain Tumor
- Brain Cancer
- mesoscale nonlinear optical microscope
-
Taipei, TaiwanDepartment of Surgery, National Taiwan University Hospital and C
Jul 4, 2023
Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Camrelizumab
- +4 more
-
Nanjing, Jiangsu, ChinaJiangsu Province Hospital
Nov 6, 2022
MRD Test in Common Risk Stage II Colorectal Cancer
Not yet recruiting
- Stage II Colorectal Cancer
- MRD test
-
Xi'an, Shaanxi, ChinaFirst Affiliated Hospital of Xian Jiaotong University
Mar 29, 2023
Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)
Not yet recruiting
- Immunotherapy;Envafolimab; Esophageal Cancer
- Envafolimab
- +2 more
- (no location specified)
Apr 24, 2023
Esophageal Carcinoma, Neoadjuvant Therapy Trial (Toripalimab, Anlotinib HCl, Albumin paclitaxel)
Not yet recruiting
- Esophageal Carcinoma
- Neoadjuvant Therapy
- Toripalimab
- +3 more
- (no location specified)
Aug 16, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023